Not Signed In - Dynavax Reports Interim TOLAMBA(TM) Ragweed Allergy Results From DARTT Trial
Tue, 09 Jan 2007 08:00 AM EST
... Dynavax Technologies Corporation (Nasdaq: DVAX) announced today that the analysis of interim one-year data from its two-year DARTT ragweed allergy trial indicated that no meaningful ragweed-specific allergic disease was observed in the study population, making it impossible to measure the therapeutic effect of TOLAMBA treatment. [click link for full article] ...
Related Topics
- Clinical Trials
- Allergy
- Latex Allergy
- Food Allergy
- Pollen
- Clemastine
- Asthma
- Shellfish
- Diphenhydramine Liquid
- Well Baby Reports
- Tuberculosis Surveillance Reports
- Chronic Disease At A Glance Reports
- Chronic Disease Notes And Reports
- Vaccine Safety and Adverse Event Reports
- Sexually Transmitted Disease Surveillance Reports
- Montelukast
- Ipratropium Bromide Oral Inhalation
- Hay Fever
- Allergy/Allergies
- Diphenhydramine Oral
email this page
print this page
bookmark this page
feedback on this page
